SMALL CELL LUNG CANCER (SCLC)

This study is observing how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer in real-world treatment settings. It will follow 500 patients who are already receiving or eligible for this treatment, tracking their survival, disease …

This early-stage study is testing a new radioactive drug called 225Ac-ABD147 for people with two aggressive types of lung cancer that have progressed after standard chemotherapy. Researchers will first determine safe doses and track where the drug goes in the body, then evaluate …

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This study is testing a new medicine called PF-08634404 when given alongside standard chemotherapy for adults with extensive-stage small cell lung cancer, a fast-spreading type of lung cancer. The research has two parts: first checking safety, then comparing the new combination t…

This is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…

This study is testing if adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery helps keep early-stage small cell lung cancer from coming back. It will enroll about 65 adults whose cancer was completely removed by surgery. The main goal is to see if this…

This early-stage study is testing a new oral drug called CP-383 in people with advanced solid tumors that have spread or returned. The main goals are to find a safe dose and see if the drug can slow or stop cancer growth. It is for patients who have run out of standard treatment …

This early-stage trial is testing a new radioactive drug called 177LuBetaBart in adults with advanced solid cancers that have stopped responding to standard treatments. The study aims to find a safe dose and see if the drug shows early signs of fighting tumors. Participants will …

This study is testing a new radioactive drug called [212Pb]Pb-DOTAM-MAM279 in adults with advanced small cell lung cancer and other hard-to-treat solid tumors. The main goals are to find a safe and effective dose and to see if the treatment can shrink tumors. The drug is designed…

This early-stage study is testing a new oral drug called VMD-928, both by itself and combined with an existing immunotherapy (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have progressed despite available treatments. The main goals are to find safe…

This early-stage study is testing a new drug called PT217 for people with advanced neuroendocrine cancers that have spread or come back after standard treatments. Researchers will first find the safest dose of PT217 given alone, then test it combined with chemotherapy. The goal i…

This early-stage study is testing a new CAR-T cell therapy called TC-D101 for people with advanced small cell lung cancer that has returned or stopped responding to standard treatments. The study will enroll 24 patients to determine the safest dose and see if the therapy shows ea…

This early-stage study is testing a new oral medication called JAB-2485 in adults with advanced solid tumors that have stopped responding to standard treatments. Researchers will first determine the safest dose and then look for early signs that the drug can shrink tumors in spec…

This study is testing a new oral medicine called mevrometostat, alone and combined with an existing drug (enzalutamide), for men with advanced prostate cancer that has worsened despite prior treatment. The main goals are to find a safe dose and see if the treatment can help contr…

This study is testing if a combination of two drugs can help control cancer growth in adults with extensive-stage small cell lung cancer. The treatment is given as a long-term 'maintenance' therapy after initial chemotherapy. Researchers will measure success by seeing if tumors s…

This study is testing different dosing schedules of an experimental drug called tarlatamab for people with advanced small cell lung cancer that has worsened after initial chemotherapy. The main goal is to see how well the drug shrinks tumors and controls the cancer. About 240 par…